WallStreetZenWallStreetZen

NASDAQ: NVNO
Envveno Medical Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NVNO stock forecasts and price targets.

Forecast return on equity

Is NVNO forecast to generate an efficient return?

Company
-51.82%
Industry
21.04%
Market
267.8%
NVNO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVNO forecast to generate an efficient return on assets?

Company
-47.17%
Industry
11.35%
NVNO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVNO earnings per share forecast

What is NVNO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.10
Avg 2 year Forecast
-$1.02
Avg 3 year Forecast
-$0.75

NVNO revenue forecast

What is NVNO's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$7.1M
Avg 3 year Forecast
$17.1M

NVNO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NVNO$0.71N/AN/A
ALUR$1.85N/AN/A
AIMD$3.30N/AN/A
COCH$0.81$9.50+1,080.12%Buy
ADGM$1.14N/AN/A
View Top Medical Device Stocks

Envveno Medical Stock Forecast FAQ

What is NVNO's earnings growth forecast for 2025-2027?

(NASDAQ: NVNO) Envveno Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 16.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.52%.

Envveno Medical's earnings in 2025 is -$21,965,000.On average, 3 Wall Street analysts forecast NVNO's earnings for 2025 to be -$22,270,139, with the lowest NVNO earnings forecast at -$21,396,801, and the highest NVNO earnings forecast at -$22,925,144. On average, 3 Wall Street analysts forecast NVNO's earnings for 2026 to be -$20,620,500, with the lowest NVNO earnings forecast at -$19,811,852, and the highest NVNO earnings forecast at -$21,226,985.

In 2027, NVNO is forecast to generate -$15,259,170 in earnings, with the lowest earnings forecast at -$14,660,771 and the highest earnings forecast at -$15,707,969.

If you're new to stock investing, here's how to buy Envveno Medical stock.

What is NVNO's revenue growth forecast for 2025-2027?

(NASDAQ: NVNO) Envveno Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.

Envveno Medical's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast NVNO's revenue for 2025 to be $0, with the lowest NVNO revenue forecast at $0, and the highest NVNO revenue forecast at $0. On average, 3 Wall Street analysts forecast NVNO's revenue for 2026 to be $144,343,497, with the lowest NVNO revenue forecast at $138,682,967, and the highest NVNO revenue forecast at $148,588,894.

In 2027, NVNO is forecast to generate $346,424,392 in revenue, with the lowest revenue forecast at $332,839,122 and the highest revenue forecast at $356,613,345.

What is NVNO's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: NVNO) forecast ROA is -47.17%, which is lower than the forecast US Medical Devices industry average of 11.35%.

What is NVNO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NVNO) Envveno Medical's current Earnings Per Share (EPS) is -$1.08. On average, analysts forecast that NVNO's EPS will be -$1.10 for 2025, with the lowest EPS forecast at -$1.06, and the highest EPS forecast at -$1.13. On average, analysts forecast that NVNO's EPS will be -$1.02 for 2026, with the lowest EPS forecast at -$0.98, and the highest EPS forecast at -$1.05. In 2027, NVNO's EPS is forecast to hit -$0.75 (min: -$0.73, max: -$0.78).

What is NVNO's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: NVNO) forecast ROE is -51.82%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.